Content area

|
|

Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin

Forfatter(e)
Birthe Gade-Rasmussen1, Sten Madsbad1, Maria Saur Svane1, Christoffer Martinussen1 & Torben Hansen2 1) Endokrinologisk Afdeling,
Hvidovre Hospital2) Novonordisk Foundation Center for Basic Metabolic Research,
Københavns Universitet

Ugeskr Læger 2018;180:V08180547
Reference: 
Ugeskr Læger 2018;180:V08180547
Sidetal: 

Birthe Gade-Rasmussen, Sten Madsbad, Maria Saur Svane, Christoffer Martinussen & Torben Hansen:

Successful treatment of KCNJ11 neonatal diabetes without insulin

Ugeskr Læger 2018;180:V08180547

In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Søren Dalsgaard | 20/05
1 Kommentar
af Anette Bygum | 19/05
10 kommentarer
af Hans-Iver G. F.-D Kley | 18/05
1 Kommentar
af Per Bonding | 17/05
1 Kommentar
af Jakob Ramlau | 15/05
1 Kommentar